340B Teaching Hospital Sues Over Medicare Part B Drug Payment Cut

The University of Kansas Medical Center sued last month over the continuation next year of a nearly 30% cut in Medicare Part B reimbursement for 340B purchased drugs.

The University of Kansas Medical Center (KUMC) has filed suit challenging the continuation in 2021 of a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B-purchased physician-administered drugs.

KUMC filed the suit Nov. 24 in U.S. District Court

Read More »

Influential House Lawmaker and Rural Hospitals Upset About J&J’s 340B Orphan Drug Policy Change

Johnson & Johnson is ending voluntary 340B drug discounts on Remicade and other Janssen brand orphan drugs to rural and free-standing cancer hospitals.

Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,”

Read More »

House Panel Holding What Might be Last Hearing of its Drug Pricing Investigation

The U.S. House Oversight and Reform Committee is holding a hearing to review the findings of its investigation into drug industry pricing and business practices.

The Democratic-led U.S. House Oversight and Reform Committee is holding a hearing this Thursday to review the findings of its nearly three-year investigation into drug industry pricing and business practices.

The Dec. 9 hearing starts at 10:30 a.m. Eastern. It’s

Read More »

Feds Say They Need Time to Decide Whether to Appeal Ruling in Novartis and United Therapeutics 340B Cases

The federal government told U.S. District Judge Dabney Friedrich it needs more time to decide whether to appeal her joint ruling in Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

The federal government on Wednesday told the judge that ruled against it in drug makers Novartis and United Therapeutics’ (UT) 340B contract pharmacy lawsuits it needs more “time to decide whether to file appeals.”

The government’s Dec. 1 statement about

Read More »

HRSA Audit Finds Drug Maker and Subsidiary Overcharged 340B Providers

Generic drug manufacturer Precision Dose and its subsidiary Tagi Pharma overcharged 340B covered entities, a HRSA audit found.

Precision Dose, a maker of liquid generic drugs in unit-dose syringes and cups, and Tagi Pharma, a wholly owned subsidiary that makes generic oral and injectable drugs, will have to repay 340B covered entities for overcharges following an 340B program

Read More »

Lilly and Feds Disagree Over Whether 340B Case Is Ripe for Appeal

Drug maker Lilly and the federal government disagree over Lilly's 340B contract pharmacy appeal to U.S. Seventh Circuit Court of Appeals.

Drug manufacturer Lilly and the federal government disagree over whether a federal district judge’s recent decision in Lilly’s 340B contract pharmacy case is ripe for review.

Last month, the U.S. Seventh Circuit Court of Appeals questioned whether U.S. Senior

Read More »

Supreme Court May Upend Medicare DSH Calculation Formula, Which Would Impact 340B Stakeholders

Supreme Court Justices announced in a June 10 order that they’d review the U.S. Court of Appeals for the D.C. Circuit’s September 2023 decision in Advocate Christ Medical Center v. Becerra.

340B hospitals’ challenge to Medicare Part B drug reimbursement cuts was not the only case on the U.S. Supreme Court docket this week that could have a significant impact on the program.

On Monday, the justices heard the case of

Read More »

News Alert: U.S. Supreme Court Justices Question CMS’s Legal Basis for Slashing 340B Hospitals’ Drug Reimbursement

The U.S. Supreme Court heard arguments today about the legality of the nearly 30% Medicare Part B drug payment cut for 340B hospitals.

Several U.S. Supreme Court justices asked during a hearing today whether the Centers for Medicare & Medicaid Services (CMS) had statutory authority to single out 340B hospitals for a nearly 30% cut in Medicare Part B drug reimbursement beginning in

Read More »

340B Providers Take Center Stage Before U.S. Supreme Court Today

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging CMS's nearly 30% cut in 340B hospitals' drug reimbursement.

The U.S. Supreme Court is hearing arguments this morning in a lawsuit challenging the nearly 30% cut since 2018 in what Medicare Part B pays hospitals for 340B-purchased physician administered drugs.

Arguments in American Hospital Association v. Becerra are due

Read More »

U.S. House GOP Conference Chair Stefanik Backs Protecting 340B Hospitals from Losing Eligibility During Pandemic

U.S. House GOP Conference Chair Elise Stefanik (N.Y.) is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Elise Stefanik, the third highest-ranking Republican in the U.S. House, is backing a bill to protect hospitals from losing their 340B eligibility due to pandemic-related changes in patient and payer mix.

Stefanik (R-N.Y.) announced her co-sponsorship of Reps. Doris

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live